Good morning, everyone. Another shiny day here on the Pharmalot corporate campus, where the short people are scampering and the dogs are barking. As always, there is much to do, especially as yet another diet pill will be reviewed today by an FDA panel. And so let the races begin. Have a great day and catch you later...
Insurers Try Incentives To Improve Med Adherence (Health Leaders)
Sanofi CEO Says Chance Of Genzyme Deal Is Reasonable (Bloomberg News)
Acne Depression Link May Not Be Due To Drugs (Reuters)
Avandia Is A PR Mess, Not A Financial Mess (Fortune)
FDA Staff Backs High-Dose Of Boehringer Clot Drug (Reuters)
Montana Governor Says Drugmakers Avoid Taxes (Bloomberg News)
Genzyme Sees End To Fabrazyme Rationing (The Wall Street Journal)
UK's NICE Says No To Glaxo Leukemia Drug (PharmaTimes)
Savient Pharm's Big Gamble Pays Off (The Star-Ledger of NJ)
Glaxo Downgraded By Analyst Ahead Of Avandia Decision (Bloomberg News)
File this under other developments: Canon Communications, which owns Pharmalot, is being sold to United Business Media (you can read about it here).
2 Comments
The link embedded in the 'UK's NICE' headline isn't correct (it is the Genzyme story URL).
Also, it is the leukaemia drug Arzerra, not COPD.
http://www.pharmatimes.com/Article/10-09-16/Setback_for_GSK_s_Arzerra_after_NICE_says_no.aspx
(sorry, just housekeeping)
Didn't GSK solicit NICE to review its drug development program a few years back in order to better avoid just these kinds of issues?